Kronos Bio has appointed Deborah Knobelman as Chief Operating Officer
Kronos Bio has appointed Deborah Knobelman as Chief Operating Officer and Chief Financial Officer.
She will oversee the finance, accounting, business development, investor relations and corporate strategy functions.
Deborah was previously Chief Financial Officer and head of corporate development for Senti Bio, a biotechnology company that utilised a synthetic biology platform to enable programming of next-generation cell therapies.
At Senti, Deborah took the company public in 2022 and was responsible for investor relations, accounting, strategic finance, financial planning and analysis, facilities, legal, portfolio management, and corporate and business development.
“I’m excited to have Deborah join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to innovate,
“Deb’s addition to our leadership team will be vital in moving our company forward and achieving our goals,” said Norbert Bischofberger, President and Chief executive officer of Kronos Bio.
“With a discovery platform that has already produced two internally discovered molecules now in development, the company’s innovative approach to targeting druggable cofactors to treat diseases of deregulated transcription is compelling,” enthused Deborah.